File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Combined-modality treatment for isolated recurrences of breast carcinoma: Update on 30 years of experience at the University of Texas M. D. Anderson Cancer Center and assessment of prognostic factors

TitleCombined-modality treatment for isolated recurrences of breast carcinoma: Update on 30 years of experience at the University of Texas M. D. Anderson Cancer Center and assessment of prognostic factors
Authors
KeywordsBreast carcinoma
Chemotherapy
Combined modality
Isolated recurrence
Stage IV-NED
Issue Date2005
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741
Citation
Cancer, 2005, v. 104 n. 6, p. 1158-1171 How to Cite?
AbstractBACKGROUND. In three prospective, single-arm studies, the authors previously showed an improved outcome for anthracycline-naïve patients with isolated sites of recurrent breast carcinoma (BC) who were treated with doxorubicin-based chemotherapy after local therapy (surgery and/or radiotherapy). In the current report, the initial results are presented from a Phase II trial of docetaxel (100 mg/m2 every 21 days for 6 cycles) given after local therapy for recurrent BC (Stage IV BC with no evidence of clinically measurable disease) in patients who received prior adjuvant anthracycline-based chemotherapy, and the authors provide an update of the 3 previous studies. An analysis of prognostic factors for these patients also is presented. METHODS. Eligibility criteria for all studies included histologic proof of recurrent BC that had been resected and/or irradiated with curative intent. Survival was calculated using the Kaplan-Meier method. Univariate survival analyses were performed to test for associations between patient characteristics and outcome (log-rank test). Cox proportional hazards models were used to determine the multivariable correlations between patient characteristics and outcome. RESULTS. The median follow-up for the docetaxel-based trial (n = 26 patients) was 45 months. Early outcomes for this study are promising. The median disease-free survival (DFS) was 44 months, and the 3-year DFS and overall survival (OS) rates were 58% and 87%, respectively. In the 3 doxorubicin-based studies, the median follow-up was 121.5 months for all living patients, and the estimated 20-year DFS and OS rates were both 26%. On multivariable analysis of patients from all 4 studies, the only significant prognostic factor for DFS and OS (P = 0.0006) was the number of involved axillary lymph nodes at initial diagnosis. CONCLUSIONS. A proportion of patients with isolated BC recurrences achieved prolonged DFS with combined-modality treatment. Patients who receive anthracycline-based chemotherapy at primary diagnosis may benefit from local treatment followed by docetaxel-based chemotherapy for isolated recurrences. The only significant independent prognostic factor was the number of involved axillary lymph nodes at initial diagnosis. © 2005 American Cancer Society.
Persistent Identifierhttp://hdl.handle.net/10722/146567
ISSN
2015 Impact Factor: 5.649
2015 SCImago Journal Rankings: 3.188
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHanrahan, EOen_HK
dc.contributor.authorBroglio, KRen_HK
dc.contributor.authorBuzdar, AUen_HK
dc.contributor.authorTheriault, RLen_HK
dc.contributor.authorValero, Ven_HK
dc.contributor.authorCrisiofanilli, Men_HK
dc.contributor.authorYin, Gen_HK
dc.contributor.authorKau, SWCen_HK
dc.contributor.authorHortobagyi, GNen_HK
dc.contributor.authorRivera, Een_HK
dc.date.accessioned2012-05-02T08:37:04Z-
dc.date.available2012-05-02T08:37:04Z-
dc.date.issued2005en_HK
dc.identifier.citationCancer, 2005, v. 104 n. 6, p. 1158-1171en_HK
dc.identifier.issn0008-543Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/146567-
dc.description.abstractBACKGROUND. In three prospective, single-arm studies, the authors previously showed an improved outcome for anthracycline-naïve patients with isolated sites of recurrent breast carcinoma (BC) who were treated with doxorubicin-based chemotherapy after local therapy (surgery and/or radiotherapy). In the current report, the initial results are presented from a Phase II trial of docetaxel (100 mg/m2 every 21 days for 6 cycles) given after local therapy for recurrent BC (Stage IV BC with no evidence of clinically measurable disease) in patients who received prior adjuvant anthracycline-based chemotherapy, and the authors provide an update of the 3 previous studies. An analysis of prognostic factors for these patients also is presented. METHODS. Eligibility criteria for all studies included histologic proof of recurrent BC that had been resected and/or irradiated with curative intent. Survival was calculated using the Kaplan-Meier method. Univariate survival analyses were performed to test for associations between patient characteristics and outcome (log-rank test). Cox proportional hazards models were used to determine the multivariable correlations between patient characteristics and outcome. RESULTS. The median follow-up for the docetaxel-based trial (n = 26 patients) was 45 months. Early outcomes for this study are promising. The median disease-free survival (DFS) was 44 months, and the 3-year DFS and overall survival (OS) rates were 58% and 87%, respectively. In the 3 doxorubicin-based studies, the median follow-up was 121.5 months for all living patients, and the estimated 20-year DFS and OS rates were both 26%. On multivariable analysis of patients from all 4 studies, the only significant prognostic factor for DFS and OS (P = 0.0006) was the number of involved axillary lymph nodes at initial diagnosis. CONCLUSIONS. A proportion of patients with isolated BC recurrences achieved prolonged DFS with combined-modality treatment. Patients who receive anthracycline-based chemotherapy at primary diagnosis may benefit from local treatment followed by docetaxel-based chemotherapy for isolated recurrences. The only significant independent prognostic factor was the number of involved axillary lymph nodes at initial diagnosis. © 2005 American Cancer Society.en_HK
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741en_HK
dc.relation.ispartofCanceren_HK
dc.subjectBreast carcinomaen_HK
dc.subjectChemotherapyen_HK
dc.subjectCombined modalityen_HK
dc.subjectIsolated recurrenceen_HK
dc.subjectStage IV-NEDen_HK
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshBreast Neoplasms - Mortality - Pathology - Therapyen_US
dc.subject.meshClinical Trials As Topicen_US
dc.subject.meshCombined Modality Therapyen_US
dc.subject.meshDoxorubicin - Administration & Dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeoplasm Recurrence, Local - Therapyen_US
dc.subject.meshNeoplasm Stagingen_US
dc.subject.meshPrognosisen_US
dc.subject.meshProportional Hazards Modelsen_US
dc.subject.meshReceptors, Estrogen - Analysisen_US
dc.subject.meshTaxoids - Administration & Dosageen_US
dc.titleCombined-modality treatment for isolated recurrences of breast carcinoma: Update on 30 years of experience at the University of Texas M. D. Anderson Cancer Center and assessment of prognostic factorsen_HK
dc.typeArticleen_HK
dc.identifier.emailYin, G: gyin@hku.hken_HK
dc.identifier.authorityYin, G=rp00831en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/cncr.21305en_HK
dc.identifier.pmid16047352-
dc.identifier.scopuseid_2-s2.0-24644470461en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-24644470461&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume104en_HK
dc.identifier.issue6en_HK
dc.identifier.spage1158en_HK
dc.identifier.epage1171en_HK
dc.identifier.isiWOS:000231743700005-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridHanrahan, EO=8558091200en_HK
dc.identifier.scopusauthoridBroglio, KR=6602915196en_HK
dc.identifier.scopusauthoridBuzdar, AU=35379841900en_HK
dc.identifier.scopusauthoridTheriault, RL=7103232796en_HK
dc.identifier.scopusauthoridValero, V=7004692933en_HK
dc.identifier.scopusauthoridCrisiofanilli, M=8558090600en_HK
dc.identifier.scopusauthoridYin, G=8725807500en_HK
dc.identifier.scopusauthoridKau, SWC=7005363979en_HK
dc.identifier.scopusauthoridHortobagyi, GN=7202399346en_HK
dc.identifier.scopusauthoridRivera, E=7101648447en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats